Literature DB >> 27664326

Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.

Lia Minculescu1, Hanne Vibeke Marquart2, Lone Smidstrup Friis3, Soeren Lykke Petersen3, Ida Schiødt3, Lars Peter Ryder2, Niels Smedegaard Andersen3, Henrik Sengeloev3.   

Abstract

Early immune reconstitution plays a critical role in clinical outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Natural killer (NK) cells are the first lymphocytes to recover after transplantation and are considered powerful effector cells in HSCT. We aimed to evaluate the clinical impact of early NK cell recovery in T cell-replete transplant recipients. Immune reconstitution was studied in 298 adult patients undergoing HSCT for acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome from 2005 to 2013. In multivariate analysis NK cell numbers on day 30 (NK30) > 150 cells/µL were independently associated with superior overall survival (hazard ratio, .79; 95% confidence interval, .66 to .95; P = .01). Cumulative incidence analyses showed that patients with NK30 > 150 cells/µL had significantly less transplant-related mortality (TRM), P = .01. Patients with NK30 > 150 cells/µL experienced significantly lower numbers of life-threatening bacterial infections as well as viral infections, including cytomegalovirus. No association was observed in relation to relapse. These results suggest an independent protective effect of high early NK cell reconstitution on TRM that translates into improved overall survival after T cell-replete HSCT.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; HSCT; Immune reconstitution; Infections; Natural killer cells; T cell replete

Mesh:

Year:  2016        PMID: 27664326     DOI: 10.1016/j.bbmt.2016.09.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

1.  Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.

Authors:  Ioannis Politikos; Jessica A Lavery; Patrick Hilden; Christina Cho; Taylor Borrill; Molly A Maloy; Sergio A Giralt; Marcel R M van den Brink; Miguel-Angel Perales; Juliet N Barker
Journal:  Blood Adv       Date:  2020-01-14

Review 2.  Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.

Authors:  Karrune V Woan; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2019-11       Impact factor: 11.151

Review 3.  The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.

Authors:  John P Veluchamy; Nina Kok; Hans J van der Vliet; Henk M W Verheul; Tanja D de Gruijl; Jan Spanholtz
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

4.  Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion.

Authors:  Emelie Rådestad; Mikael Sundin; Johan Törlén; Sarah Thunberg; Björn Önfelt; Per Ljungman; Emma Watz; Jonas Mattsson; Michael Uhlin
Journal:  Front Immunol       Date:  2019-02-11       Impact factor: 7.561

Review 5.  Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.

Authors:  Elisa Zaghi; Michela Calvi; Clara Di Vito; Domenico Mavilio
Journal:  Front Immunol       Date:  2019-11-28       Impact factor: 7.561

Review 6.  Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.

Authors:  Claudio Annaloro; Fabio Serpenti; Giorgia Saporiti; Giulia Galassi; Francesca Cavallaro; Federica Grifoni; Maria Goldaniga; Luca Baldini; Francesco Onida
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

7.  Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide.

Authors:  Yoshinobu Maeda
Journal:  J Clin Exp Hematop       Date:  2021-02-06

8.  Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Authors:  Muhammad Umair Mushtaq; Moazzam Shahzad; Amna Y Shah; Sibgha Gull Chaudhary; Muhammad U Zafar; Iqra Anwar; Karun Neupane; Ayesha Khalid; Nausheen Ahmed; Rajat Bansal; Ramesh Balusu; Anurag K Singh; Sunil H Abhyankar; Natalie S Callander; Peiman Hematti; Joseph P McGuirk
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

9.  Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.

Authors:  Lia Minculescu; Anne Fischer-Nielsen; Eva Haastrup; Lars Peter Ryder; Niels Smedegaard Andersen; Ida Schjoedt; Lone Smidstrup Friis; Brian Thomas Kornblit; Søren Lykke Petersen; Henrik Sengelov; Hanne Vibeke Marquart
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.